SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : Taking Advantage of a Sharply Changing Environment
NRG 168.59+3.0%3:59 PM EST

 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Doug R who wrote (2871)1/25/2020 11:32:03 AM
From: Doug R1 Recommendation

Recommended By
Hawkmoon

  Read Replies (1) of 6337
 
Besides LaPointe's work, some additional positive news, there's a highly likely, real, cancer breakthrough.
These two things are of a class that can have a significant role in wresting levers of control/"power"
from the control freak "powers that be", and slowing their roll toward "smart" city/surveillance/compliance/fake food hell...if not derailing it.

British Scientists May Have Found Cure For Cancer. By Accident.
dailywire.com

What makes this new discovery so exciting is that prior therapies, referred to as CAR-T and TCR-T therapies, which use immune cells to attach to HLA molecules on cancer cells’ surface, fight cancer but are incapable of fighting solid tumors. As The Telegraph points out, HLA molecules vary in people, but the new therapy attaches to a molecule called MR1, which does not vary in humans, which gives it the chance of fighting most cancers and additionally means people could share the treatment, allowing banks of the cells to be stored and thus be offered quickly to people suffering from the disease.

Immune cells from the new treatment have killed lung, skin, blood, colon, breast, bone, prostate, ovarian, kidney and cervical cancer cells. The study stated:

"Human leukocyte antigen (HLA)-independent, T cell-mediated targeting of cancer cells would allow immune destruction of malignancies in all individuals. Here, we use genome-wide CRISPR-Cas9 screening to establish that a T cell receptor recognized and killed most human cancer types via the monomorphic MHC class-I related protein, MR1, while remaining inert to noncancerous cells … These finding offer opportunities for HLA-independent, pan-cancer, pan-population immunotherapies."
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext